Dr Williams is CEO of the Global Snakebite Initiative, an IST-endorsed non-profit organisation providing international advocacy for improved access to effective
treatment for snakebite envenoming. The Global Snakebite Initiative are leading international efforts to have snakebite envenoming restored to the WHO list of Neglected
Tropical Diseases, and to obtain Member State support for a resolution on a WHO-wide snakebite mitigation program at the 2017 World Health Assembly.
He is the editor of the second edition of the WHO’s Guidelines for the Production Control and Regulation of Snake Antivenom Immunoglobulins, and is the Head of Australian
Venom Research Unit, in the Department of Pharmacology and Therapeutics at the University of Melbourne, and the Charles Campbell Toxinology Centre at the School
of Medicine and Health Sciences of the University of Papua New Guinea, leading a combined team focused on preclinical and clinical toxinology research and venomous
His team have collaborated with international partners to develop and conduct clinical trials of a new, high potency antivenom for treating Papuan taipan
(Oxyuranus scutellatus) envenoming in Papua New Guinea, and to introduce a holistic multidisciplinary action plan that has reduced snakebite mortality very significantly.
Dr Williams is now partnering with a growing coalition of Indian stakeholders to develop an effective pathway to the creation of a new generation of Indian polyvalent
antivenoms and other snakebite interventions.
back to speaker page